Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

GemVax announced phase II results of GV1001 for Alzheimer's disease treatment at CTAD 2019

prnasiaDecember 16, 2019

Tag: GemVax , GV1001 , phase II results

PharmaSources Customer Service